Biotech News
Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel
– Analysis of ATEVs from 52 patients across five clinical trials, some implanted for more than five years, found minimal lipid buildup and no evidence of vulnerable plaques. – First long-term clinical evaluation of atherosclerosis susceptibility in a tissue engineered vessel. DURHAM, N.C., Nov.
